Role of adipokines in regulation of colonic motor activity in overweight and obese individuals
https://doi.org/10.33667/2078-5631-2021-35-48-51
Abstract
The increasing proportion of the population suffering from overweight or obesity is now taking on the character of a pandemic. In the literature, there have begun to appear reports of associations in individuals with impaired colonic motility and a body mass index above 25 kg/m2. The present publication was prepared to systematize data on possible mechanisms of colonic motility disorders in overweight and obese individuals, including through changes in adipokine secretion and function. The literature search was performed in Embase, PubMed, and Google Scholar, using the key words ‘colon motility regulation’, ‘adipokines’, ‘gastrointestinal hormones’, ‘intestinal microbiota’, ‘overweight’, ‘obesity’, ‘visceral fat’.
Supporting agencies: The publication was prepared with funding from a grant from the President of the Russian Federation for state support of leading scientific schools (NSh2558.2020.7) (agreement No. 075–15–2020–036 of March 17, 2020) ′Development of a technology for health preservation of a comorbid gastroenterological patient based on adherence control′
About the Authors
М. М. Fedorin
Omsk State Medical University
Russian Federation
Russian Federation
Fedorin Maksim M. - resident at Dept of Faculty Therapy and Gastroenterology
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
Livzan Maria A. - DM Sci (habil.), professor, rector, head of Dept of Faculty Therapy and Gastroenterology
O. V. Gaus
Omsk State Medical University
Russian Federation
Russian Federation
Gaus Olga V. - PhD Med, associate professor at Dept of Faculty Therapy and Gastroenterology
References
1. M. Ng. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384 (9945): 766–781. https://doi.org/10.1016/S0140–6736(14)60460–8
2. Matoshina I. V., Fedorin M. M., Livzan M. A., Mozgovoy S. I. Resistance of the esophageal mucosa in patients with GERD: the dialogue between clinician and pathologist (in Russ.). Effective pharmacotherapy. 2021; 17 (4): 34–39. https://doi.org/10.33978/2307–3586–2021–17–4–34–39
3. Livzan M. A., Osipenko M. F. Syndrome of intersection of functional diseases of the digestive tract (in Russ.). RMJ. 2012; 20 (15): 768–770.
4. Livzan M. A., Kolbina M. V., Matoshina I. V., et al. Hormones adipose tissue and non-alcoholic fatty liver disease at metabolic syndrome (in Russ.). Diary of Kazan Medical School. 2014; 1 (4): 44–48.
5. Gaus O. V., Livzan M. A. Irritable bowel syndrome: what do we know about symptoms today? (In Russ.). Consilium Medicum. 2019; 21(8): 42–48. https://doi.org/10.26442/20751753.2019.8.190512
6. Blüher M., Mantzoros C. S. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015; 64 (1): 131–145. https://doi.org/10.1016/j.metabol.2014.10.016
7. Fedorin М. М., Gaus O. V., Livzan M. A., Sukhanova S. A. Typical dietary habits and elevated intestinal permeability in people with excess body weight and IBS (In Russ.). Experimental and Clinical Gastroenterology. 2021; 190 (6): 50–56. https://doi.org/10.31146/1682–8658-ecg-190–6–50–56
8. Eswaran S., Tack J., Chey W. D. Food: the forgotten factor in the irritable bowel syndrome.Gastroenterol. Clin North Am. 2011. 40 (1): 141–162. https://doi.org/10.1016/j.gtc.2010.12.012 9.
9. Livzan M. A., Nikolaev N. A., Skirdenko Yu.P., et al. Nutritional behavior in a student community (in Russ.). Kremlin Medicine Journal. 2019; (2): 13–16. https://doi.org/10.26269/tvs8-by34
10. Karamnova N. S., Shalnova S. А., Deev А. D., et al. Nutrition characteristics of adult inhabitants by ESSE-RF study (in Russ.). Cardiovascular Therapy and Prevention. 2018; 17(4): 61–66. http://doi.org/10.15829/1728–8800–2018–4–61–66
11. Khayyatzadeh S. S., Esmaillzadeh A., Saneei P., et al. Dietary patterns and prevalence of irritable bowel syndrome in Iranian adults. Neurogastroenterol Motil. 2016; 28 (12): 1921–1933. https://doi.org/10.1111/nmo.12895
12. Salari-Moghaddam A., Keshteli A. H., Esmaillzadeh A., Adibi P. Adherence to the pro-inflammatory diet in relation to prevalence of irritable bowel syndrome. Nutr J. 2019; 18 (1): 72. https://doi.org/10.1186/s12937–019–0487–6
13. Suhanova S. A., Timakova A. Yu., Livzan M. A., et al. Adherence to treatment of patients with irritable bowel syndrome: state of the issue (in Russ.). The Russian Journal of Preventive Medicine. 2021; 24 (8): 101–108. https://doi.org/10.17116/profmed202124081101
14. Ortega F. B., Cadenas-Sanchez C., Migueles J. H., et al. Role of Physical Activity and Fitness in the Characterization and Prognosis of the Metabolically Healthy Obesity Phenotype: A Systematic Review and Meta-analysis. Prog Cardiovasc Dis. 2018; 61 (2): 190–205. https://doi.org/10.1016/j.pcad.2018.07.008
15. Cronin O., Molloy M. G., Shanahan F. Exercise, fitness, and the gut. Curr Opin Gastroenterol. 2016; 32 (2): 67–73. https://doi.org/10.1097/MOG.0000000000000240
16. Stanich P., Peck J., Murphy C., et al. Physical activity during video capsule endoscopy cor-relates with shorter bowel transit time. Endosc. Int. Open. 2015; 5 (9): E 856–E 860. https://doi. org/10.1055/s-0043–115385
17. Wilson P. B. Associations between physical activity and constipation in adult Americans: Results from the National Health and Nutrition Examination Survey. Neurogastroenterol Motil. 2020; 32 (5): e13789. https://doi.org/10.1111/nmo.13789
18. Upadhyay J., Farr O., Perakakis N., et al. Obesity as a Disease. Med Clin North Am. 2018; 102 (1): 13–33. https://doi.org/10.1016/j.mcna.2017.08.004
19. Karczewski J., Śledzińska E., Baturo A. et al. Obesity and inflammation. Eur Cytokine Netw. 2018; 29 (3): 83–94. https://doi.org/10.1684/ecn.2018.0415
20. Gruzdeva O., Borodkina D., Uchasova E., et al. Leptin resistance: underlying mechanisms and di-agnosis. Diabetes Metab Syndr Obes. 2019; (12): 191–198. https://doi.org/10.2147/DMSO.S 182406
21. Wada N., Hirako S., Takenoya F., et al. Leptin and its receptors. J. Chem. Neuroanat. 2014; (61): 191–199. https://doi.org/10.1016/j.jchemneu.2014.09.002
22. Morris D. L., Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab. 2009; 297 (6): E 1247–E 1259. https://doi.org/10.1152/ajpen-do.00274.2009
23. Gautron L., Elmquist J. K. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest. 2011; 121 (6): 2087–2093. https://doi.org/10.1172/JCI45888
24. Livzan M. A., Lapteva I. V., Miller T. S. Role leptin and leptinresistance to organization non al-coholic fatty liver disease in persons with obesity and overweight (in Russ.). Experimental and Clinical Gastroenterology. 2014; 108 (8): 27–33.
25. Liu D. R., Xu X. J., Yao S. K. Increased intestinal mucosal leptin levels in patients with diarrhea-pre-dominant irritable bowel syndrome. World J Gastroenterol. 2018; 24 (1): 46–57. https://doi.org/10.3748/wjg.v24.i1.46
26. Russo F., Chimienti G., Clemente C. et al. Adipokine profile in celiac patients: differences in comparison with patients suffering from diarrhea-predominant IBS and healthy subjects. Scand J Gastroenterol. 2013; 48 (12): 1377–1385. https://doi.org/10.3109/00365521.2013.845907
27. Choi H. M., Doss H. M., Kim K. S. Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int J Mol Sci. 2020; 21 (4): 1219. https://doi.org/10.3390/ijms21041219
28. Katsareli E. A., Dedoussis G. V. Biomarkers in the field of obesity and its related comorbidities. Expert Opin Ther Targets. 2014; 18 (4): 385–401. https://doi.org/10.1517/14728222.2014.882321
29. Tracey D. J., Walker J. S. Pain due to nerve damage: are inflammatory mediators involved? Inflamm Res. 1995; 44 (10): 407–411. https://doi.org/10.1007/BF01757696
30. Karra E., Chandarana K., Batterham R. L. The role of peptide YY in appetite regulation and obesity. J Physiol. 2009; 587 (1): 19–25. https://doi.org/10.1113/jphysiol.2008.164269
31. Neary M. T., Batterham R. L. Peptide Y. Y.: food for thought. Physiol Behav. 2009; 97 (5): 616–619. https://doi.org/10.1016/j.physbeh.2009.02.024
32. El-Salhy M., Gilja O. H., Gundersen D., et al. Endocrine cells in the ileum of patients with irritable bowel syndrome. World J Gastroenterol. 2014; 20 (9): 2383–2391. https://doi.org/10.3748/wjg.v20.i9.2383
33. El-Salhy M., Hatlebakk J. G., Hausken T. Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides. 2020; (79): 101973. https://doi.org/10.1016/j.npep.2019.101973
34. El-Salhy M., Hatlebakk J. G., Gilja O. H., Hausken T. Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides. 2015; 67: 12–9. https://doi.org/10.1016/j.peptides.2015.02.008
35. Hillman J. B., Tong J., Tschop M. Ghrelin biology and its role in weight-related disorders. Discov Med. 2011; 11 (61): 521–528.
36. Solomou S., Korbonits M. The role of ghrelin in weight-regulation disorders: implications in clinical practice. Hormones (Athens). 2014; 13 (4): 458–475. https://doi.org/10.14310/horm.2002.1551
37. El-Salhy M., Lillebø E., Reinemo A., Salmelid L. Ghrelin in patients with irritable bowel syndrome. Int J Mol Med. 2009; 23 (6): 703–707. https://doi.org/10.3892/ijmm_00000183
38. El-Salhy M., Gilja O. H., Gundersen D., Hausken T. Endocrine cells in the oxyntic mucosa of the stomach in patients with irritable bowel syndrome. World J Gastrointest Endosc. 2014; 6 (5): 176–185. https://doi.org/10.4253/wjge.v6.i5.176
39. Şahin-Eryılmaz G., Başak K., Çakır-Madenci Ö., et al. Relationship between irritable bowel syndrome and plasma and tissue ghrelin levels. Turk J Gastroenterol. 2018; 29 (6): 631–635. https://doi.org/10.5152/tjg.2018.17593
40. Kolodziejczyk A. A., Zheng D., Elinav E. Diet-microbiota interactions and personalized nutrition. Nat Rev Microbiol. 2019; 17 (12): 742–753. https://doi.org/10.1038/s41579–019–0256–8
41. Stephens R. W., Arhire L., Covasa M. Gut Microbiota: From Microorganisms to Metabolic Organ Influencing Obesity. Obesity (Silver Spring). 2018; 26 (5): 801–809. https://doi.org/10.1002/oby.22179
42. Wan Y., Wang F., Yuan J., et al. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. Gut. 2019; 68 (8): 1417–1429. https://doi.org/10.1136/gutjnl-2018–317609
43. Rajilić-Stojanović M., Biagi E., Heilig H. G., et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011; 141 (5): 1792–1801. https://doi.org/10.1053/j.gastro.2011.07.043
Review
For citations:
Fedorin М.М., Livzan M.A., Gaus O.V. Role of adipokines in regulation of colonic motor activity in overweight and obese individuals. Medical alphabet. 2021;(35):48-51. (In Russ.) https://doi.org/10.33667/2078-5631-2021-35-48-51
Views:
271
Email this article 